Tuesday, September 26, 2023


Biotechnology News Magazine

Mike Sismour, PhD and Mark Rees, PhD Ultivue New Executive Team Members

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Mike Sismour, Ph.D. has joined Ultivue in the role of Vice President, Research, and Mark Rees, Ph.D. has joined as Vice President, Corporate Development.

Mike has a background enabling innovative solutions in the biotechnology and diagnostics industries. He brings extensive experience in nucleic acid chemistry/enzymology, in situ biomolecule detection, multiplexed biomolecule analysis, and sequencing system development. He was an NIH Ruth L. Kirschstein Postdoctoral Fellow at Harvard Medical School, a fellow at the Wyss Institute at Harvard, and most recently was Chief Scientist/Head of Genomics R&D at Beckman Coulter Life Science.

“Ultivue has an amazing technology platform and I am very excited to join their growing team,” says Mike. “Their innovations are pushing boundaries in what is technically achievable in complex assays while bringing a robust, simple solution to the customer.”

Mark joins Ultivue with over two decades of leadership experience in scientific affairs and business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform, as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs, and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher), and Novocastra Laboratories.

According to Mark, “I am very excited to be joining the executive team at Ultivue. Ultivue has the best in class multiplex IF technology platform, which together with their rapid custom service, can deliver high-quality complex assay solutions to Biopharma and CRO partners in record turnaround times.”

“It’s an exciting time for us at Ultivue,” notes Jacques Corriveau, President, and CEO. “The combination of Mike’s ability to iterate on current technology and innovate on future offerings, alongside Mark further enabling these advancements within our partnership ecosystem, will help our customers bring exciting new therapies to market and positively impact the drive for personalized cancer treatment.”


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine